Ad
Search
Generic filters
Filter by content type
Taxonomy terms

TNXP – Tonix Pharmaceuticals Holding Corp

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 40.67

Low: 10

High: 96

Total Analysts: 3

Company Profile

Tonix Pharmaceuticals Holding Corp. (Tonix) is a clinical-stage biopharmaceutical company. It is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses